Pericyte loss in Alzheimer's disease leads to proteolytic shedding of PDGFRβ into circulation, providing a blood-accessible marker of pericyte injury. Circulating PDGFRβ correlates with BBB permeability and cognitive decline. Critical weakness: PDGFRβ is not pericyte-specific (expressed on vascular smooth muscle cells, fibroblasts, hepatic stellate cells), making source attribution essential before clinical deployment.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Abeta deposition"] --> B["Pericyte injury and loss"]
B --> C["PDGFRbeta proteolytic shedding"]
C --> D["Soluble PDGFRbeta in circulation"]
D --> E["BBB permeability increase"]
E --> F["Neurotoxin extravasation into CNS"]
F --> G["Synapse loss and neuronal dysfunction"]
G --> H["Cognitive decline"]
B --> I["PDGFRbeta polymorphisms increase AD risk"]
J["Therapeutic: PDE3A inhibition"] --> K["Enhanced pericyte survival"]
K --> B
D --> L["Source attribution challenge (VSMC, fibroblasts, hepatic stellate cells)"]
L -.-> H
style A fill:#ef5350,stroke:#c62828,color:#fff
style B fill:#ef5350,stroke:#c62828,color:#fff
style C fill:#4fc3f7,stroke:#0288d1,color:#000
style D fill:#4fc3f7,stroke:#0288d1,color:#000
style E fill:#ef5350,stroke:#c62828,color:#fff
style F fill:#ef5350,stroke:#c62828,color:#fff
style G fill:#ef5350,stroke:#c62828,color:#fff
style H fill:#ffd54f,stroke:#f9a825,color:#000
style I fill:#ef5350,stroke:#c62828,color:#fff
style J fill:#81c784,stroke:#388e3c,color:#000
style K fill:#81c784,stroke:#388e3c,color:#000
style L fill:#ffd54f,stroke:#f9a825,color:#000
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMIDValidation: 0%3 supporting / 3 opposing
✓For(3)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
2
1
MECH 3CLIN 2GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Pericyte loss precedes neurodegeneration in AD mod…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic Hypotheses: BBB Permeability Biomarkers in Neurodegeneration
Hypothesis 1: Circulating PDGFRβ as a Pericyte-Specific BBB Integrity Marker
Title: Soluble PDGFRβ as a Peripheral Indicator of Pericyte-Mediated Blood-Brain Barrier Breakdown in Preclinical Neurodegeneration
Description: Loss of brain pericytes represents one of the earliest detectable pathological events in Alzheimer's disease, preceding amyloid deposition. Pericytes maintain BBB integrity through PDGF-BB/PDGFRβ signaling, and proteolytic shedding of PDGFRβ into circulation provides a blood-access
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation: BBB Permeability Biomarkers in Neurodegeneration
Hypothesis 1: Circulating PDGFRβ as Pericyte-Specific BBB Integrity Marker
Original Confidence: 0.78
Specific Weaknesses
Lack of Cellular Specificity: PDGFRβ is not pericyte-specific. It is expressed on vascular smooth muscle cells, perivascular fibroblasts (PMID: 24012480), hepatic stellate cells, and various immune cell populations. Circulating PDGFRβ cannot be attributed to brain pericytes without source validation.
Ambiguous Shedding Mechanism: The proteolytic events leading to solu
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Practical Feasibility Assessment: BBB Permeability Biomarkers in Neurodegeneration
Preamble: Overarching Methodology Concerns
Before assessing individual hypotheses, a common structural issue undermines all seven: none of these biomarkers have been validated against a gold-standard human BBB permeability measurement (e.g., dynamic contrast-enhanced MRI with gadobutrin, or CSF/serum albumin ratios with concurrent plasma sampling). The entire field risks building a biomarker panel on correlative data with uncharacterized specificity windows. This fundamentally constrains the th
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses": [{"title": "Matrix Metalloproteinase-9 and TIMP-1 Ratio in Peripheral Blood as an Early Indicator of BBB Tight Junction Proteolysis", "description": "Elevated MMP-9/TIMP-1 ratio reflects net proteolytic activity against the BBB, causing degradation of tight junction proteins (claudin-5, occludin, ZO-1) and increased permeability. This imbalance precedes measurable cognitive decline and represents a blood-accessible biomarker. The hypothesis has the strongest evidence base with the additional advantage of having clinically plausible interventions available for repurposin
If soluble PDGFRβ in plasma reflects pericyte degeneration, then sPDGFRβ will correlate with the rate of BBB integrity decline (DCE-MRI Ktrans slope) and with cognitive deterioration rate, independent of amyloid plaque burden and brain atrophy.
pendingconf: 0.50
Expected outcome: In a 2-year longitudinal AD cohort (n≥100 with amyloid PET, DCE-MRI, and plasma sPDGFRβ), baseline sPDGFRβ in top tertile predicts accelerated Ktrans decline (>30% reduction/year) and MMSE decline rate >2x faster, after adjustment for amyloid SUVR and hippocampal volume.
Falsified by: sPDGFRβ does not predict BBB decline rate or cognitive trajectory after adjustment for amyloid and atrophy; pericyte marker changes are secondary to neurodegeneration markers, not independent drivers.
Method: Longitudinal AD cohort: plasma sPDGFRβ, DCE-MRI, amyloid PET, MRI atrophy, and cognitive testing at baseline and 12/24 months; mixed-effects models for biomarker trajectories and pericyte contribution independent of amyloid.